Subscribe
shutterstock_580492693_akedesign
akedesign / Shutterstock.com
9 March 2021Big PharmaRory O' Neill

WHO head calls for IP waiver to beat COVID-19

The director general of the World Health Organization (WHO) has called for a waiver on IP rights to ensure more equitable access to COVID-19 vaccines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
India calls for IP waiver to combat COVID-19
2 March 2021   The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.
Medtech
Senator calls on Biden to reject COVID IP waiver
2 March 2021   Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Big Pharma
WHO urges vigilance against fake COVID-19 vaccines
29 March 2021   The World Health Organization has warned the public of the danger of counterfeit COVID-19 vaccines and urged people not to procure jabs outside of government channels.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Medtech
India calls for IP waiver to combat COVID-19
2 March 2021   The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.
Medtech
Senator calls on Biden to reject COVID IP waiver
2 March 2021   Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Big Pharma
WHO urges vigilance against fake COVID-19 vaccines
29 March 2021   The World Health Organization has warned the public of the danger of counterfeit COVID-19 vaccines and urged people not to procure jabs outside of government channels.

More on this story

Medtech
India calls for IP waiver to combat COVID-19
2 March 2021   The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.
Medtech
Senator calls on Biden to reject COVID IP waiver
2 March 2021   Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Big Pharma
WHO urges vigilance against fake COVID-19 vaccines
29 March 2021   The World Health Organization has warned the public of the danger of counterfeit COVID-19 vaccines and urged people not to procure jabs outside of government channels.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York